Clinical Trials
43 trialsMK-1026-003
Merck Sharp & Dohme LLC
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
ACCESS
Center for International Blood and Marrow Transplant Research
ACCELERATE
Center for International Blood and Marrow Transplant Research
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
French Innovative Leukemia Organisation
PIPOZA
Peter MacCallum Cancer Centre, Australia
CLL2-BZAG
German CLL Study Group
CLL-Frail
German CLL Study Group
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
ACALLO
Polish Lymphoma Research Group
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
CLL2-BAAG
German CLL Study Group
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Nanfang Hospital, Southern Medical University
UK-Haplo
University College, London
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
National Institutes of Health Clinical Center (CC)
IDEAL2
Therapeutic Advances in Childhood Leukemia Consortium
STELLAR
University of Birmingham
HLA
University of Liege
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
German CLL Study Group
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The First Affiliated Hospital with Nanjing Medical University
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
CLEAR
King's College Hospital NHS Trust
Stem Cell Transplantation for Patients With Cancers of the Blood
National Institutes of Health Clinical Center (CC)
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
GlaxoSmithKline
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
MedImmune LLC
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Rev-CLL
University Health Network, Toronto
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
Stanford University
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
GlaxoSmithKline
BIFROST
GlaxoSmithKline
R-CHOP
CABYC
RESPeCT
The Christie NHS Foundation Trust
LT-CLL-001
Vilnius University
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Royal Marsden NHS Foundation Trust
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Cylene Pharmaceuticals
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
Titan Pharmaceuticals